

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCY
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/814,752	03/31/2004	Paul L. DeAngelis	4599.014	8611
30589 75	90 07/25/2006		EXAMINER	
DUNLAP, CODDING & ROGERS P.C.			SLOBODYANSKY, ELIZABETH	
PO BOX 16370 OKLAHOMA CITY, OK 73113			ART UNIT	PAPER NUMBER
	•		1652	

DATE MAILED: 07/25/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Commons	10/814,752	DEANGELIS, PAUL L.				
Office Action Summary	Examiner	Art Unit				
	Elizabeth Slobodyansky, PhD	1652				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communion.  - If NO period for reply is specified above, the maximum statutory period was realized to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	l. ely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
•	action is non-final.					
=	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-18</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-18 are subject to restriction and/or e	8) Claim(s) 1-18 are subject to restriction and/or election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
<ol> <li>Certified copies of the priority documents have been received.</li> </ol>						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attach was and Co						
Attachment(s)  1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO_413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	te				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5)  Notice of Informal P 6) Other:	atent Application (PTO-152)				

Application/Control Number: 10/814,752 Page 2

Art Unit: 1652

## **DETAILED ACTION**

This application is a CIP of copending application 10/142,143.

Claims 1-18 are pending.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-7 and 10-13 (in part), drawn to a nucleic acid encoding heparin synthase of SEQ ID NOs: 13 or 15, classified in class 536, subclass 23.2.
- II. Claims 8, 9 and 14-18, drawn to methods for producing heparin polymer using heparin synthase, classified in class 435, subclass 101.
- III. Claims 10-13 (in part), drawn to a nucleic acid encoding heparin synthase of SEQ ID NOs: 2, 4, 6, 25, 27 or 34, classified in class 536, subclass 23.2.

For each of inventions I-III above, restriction to one of the following is also required under 35 USC 121. Therefore, election is required of one of inventions I-III and one of inventions (A)-(H).

- (A). SEQ ID No: 1 or a sequence encoding SEQ ID No: 2.
- (B). SEQ ID No: 3 or a sequence encoding SEQ ID No: 4.
- (C). SEQ ID No: 5 or a sequence encoding SEQ ID No: 6.
- (D). SEQ ID No: 12 or a sequence encoding SEQ ID No: 13.
- (E). SEQ ID No: 14 or a sequence encoding SEQ ID No: 15.
- (F). SEQ ID No: 24 or a sequence encoding SEQ ID No: 25.
- (G). SEQ ID No: 26 or a sequence encoding SEQ ID No: 27.
- (H). SEQ ID No: 33 or a sequence encoding SEQ ID No: 34.

Art Unit: 1652

The inventions are distinct, each from the other because of the following reasons: Inventions (A)-(H) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions, represent structurally different nucleic acids. Therefore, where structural identity is required, such as for hybridization or expression, the different sequences have different effects.

Inventions I, III and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the process can be used for producing polymers of different lengths and heparin synthase can be used for the production of antibodies.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Art Unit: 1652

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth Slobodyansky, PhD whose telephone number is 571-272-0941. The examiner can normally be reached on M-F 10:00 - 6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, PhD can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

S. Slobodyonsky, PhD

Primary Examiner Art Unit 1652